Application of IVIM-DWI in Detecting the Tumor Vasculogenic Mimicry Under Antiangiogenesis Combined With Oxaliplatin Treatment by Jianye Liang, Jianye Liang, Zhipeng Li, Jing Li, Chuan Peng, Wei Dai, Haoqiang He, Sihui Zeng, Chuanmiao Xie

“…Simultaneously, we evaluated the tumor invasiveness and vasculogenic mimicry and performed synthetic assessment of treatment efficacy of angiogenesis inhibitor combined with conventional chemotherapy using IVIM-DWI.Materials and Methods: HCT116 cells were subcutaneously administered into the right flank of BALB/C nude mice to build a colon cancer xenograft model. …”
Get full text

Identification of TRAPPC9 and BAIAP2 Gene Polymorphisms and Their Association With Fat Deposition-Related Traits in Hu Sheep by Panpan Cui, Weimin Wang, Weimin Wang, Deyin Zhang, Chong Li, Yongliang Huang, Zongwu Ma, Xiaojuan Wang, Liming Zhao, Yukun Zhang, Xiaobin Yang, Dan Xu, Jiangbo Cheng, Xiaolong Li, Xiwen Zeng, Yuan Zhao, Wenxin Li, Jianghui Wang, Changchun Lin, Bubo Zhou, Jia Liu, Rui Zhai, Xiaoxue Zhang

“…In addition, single nucleotide polymorphisms and the expression characteristics of TRAPPC9 (encoding trafficking protein particle complex subunit 9) and BAIAP2 (encoding brain-specific Angiogenesis inhibitor 1-associated protein 2) genes in Hu sheep were detected using PCR amplification, Sanger sequencing, KASPar genotyping, and quantitative real-time reverse transcription PCR (qRT-PCR). …”
Get full text

Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14–3-3η/NF-κB feedback loop by Yongxin Qiu, Yi Dai, Chi Zhang, Ye Yang, Ming Jin, Wenqi Shan, Jian Shen, Ming Lu, Zhaoyang Tang, Liang Ju, Yuting Wang, Ruonan Jiao, Yunwei Xia, Guangming Huang, Lihua Yang, Yuan Li, Jianping Zhang, Vincent Kam Wai Wong, Zhihong Jiang

“…We have previously identified arsenic trioxide (ATO) as an effective metastasis/angiogenesis inhibitor in HCC. Here, we further found that MDR-HCC cells were more sensitive to ATO. …”
Get full text

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells by Luca Hegedüs, Kata D. Szücs, Matthias Kudla, Julian Heidenreich, Julian Heidenreich, Verena Jendrossek, Samuel Peña-Llopis, Samuel Peña-Llopis, Tamas Garay, Tamas Garay, Andras Czirok, Clemens Aigner, Till Plönes, Silvia Vega-Rubin-de-Celis, Balazs Hegedüs

“…Nintedanib (BIBF1120) is a small-molecule tyrosine kinase inhibitor that showed promising efficacy preclinically and in phase II trial in MPM as an angiogenesis inhibitor combined with chemotherapy. However, the extended phase III trial failed. …”
Get full text

Coral-Derived Compound WA-25 Inhibits Angiogenesis by Attenuating the VEGF/VEGFR2 Signaling Pathway by Shih-Wei Lin, Shih-Chung Huang, Hsiao-Mei Kuo, Chiu-Hua Chen, Yi-Ling Ma, Tian-Huei Chu, Youn-Shen Bee, E-Ming Wang, Chang-Yi Wu, Ping-Jyun Sung, Zhi-Hong Wen, Deng-Chyang Wu, Jyh-Horng Sheu, Ming-Hong Tai

“…Conclusions: WA-25 is a potent angiogenesis inhibitor that acts through the down-regulation of VEGF and VEGFR2 in endothelial cells. …”
Get full text

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial by Song-Yang Wu, Ying Xu, Li Chen, Lei Fan, Xiao-Yan Ma, Shen Zhao, Xiao-Qing Song, Xin Hu, Wen-Tao Yang, Wen-Jun Chai, Xiao-Mao Guo, Xi-Zi Chen, Yan-Hui Xu, Xiao-Yu Zhu, Jian-Jun Zou, Zhong-Hua Wang, Yi-Zhou Jiang, Zhi-Ming Shao

“…We conducted the phase II FUTURE-C-Plus trial to assess the feasibility of combining famitinib (an angiogenesis inhibitor), camrelizumab (a PD-1 monoclonal antibody) and chemotherapy in advanced immunomodulatory TNBC patients. …”
Get full text

Chicken Embryo as Model for Effects of Nnitrosodimethylamine Using Morphology, Haematology and Proteomic Analyses During Embryogenesis by Sulaiman, Mohd Rosni

“…In conclusion, NDMA in its normal carcinogenic dosage could potentially cause developmental toxicity in the early and mid embryogenesis of chicken through its possible primary role as an angiogenesis inhibitor and/or secondary role as a hematotoxicant. …”
Get full text

Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC... by Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Yoshinori Kagawa, Naoki Takahashi, Tadamichi Denda, Taito Esaki, Hisato Kawakami, Hironaga Satake, Atsuo Takashima, Nobuhisa Matsuhashi, Takeshi Kato, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino

“…Several plasma angiogenesis factors showed significant change at progression in 1L chemotherapy plus biologics for RAS wild‐type mCRC, which are potential biomarkers for selecting an optimal angiogenesis inhibitor in second‐line treatment.…”
Get full text

Anti-Angiogenetic and Anti-Lymphangiogenic Effects of a Novel 2-Aminobenzimidazole Derivative, MFB by Ming-Jen Hsu, Ming-Jen Hsu, Ming-Jen Hsu, Han-Kun Chen, Cheng-Yu Chen, Cheng-Yu Chen, Cheng-Yu Chen, Cheng-Yu Chen, Cheng-Yu Chen, Jin-Cherng Lien, Jin-Cherng Lien, Jing-Yan Gao, Jing-Yan Gao, Yu-Han Huang, Yu-Han Huang, Justin Bo-Kai Hsu, Justin Bo-Kai Hsu, Gilbert Aaron Lee, Gilbert Aaron Lee, Gilbert Aaron Lee, Shiu-Wen Huang, Shiu-Wen Huang, Shiu-Wen Huang, Shiu-Wen Huang, Shiu-Wen Huang

“…In this study, we aim to investigate the anti-angiogenic mechanisms of MFB, a novel 2-aminobenzimidazole derivative, to develop a novel angiogenesis inhibitor.Experimental ApproachMTT, BrdU, migration and invasion assays, and immunoblotting were employed to examine MFB’s effects on vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, migration, invasion, as well as signaling molecules activation. …”
Get full text

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy by Ming Zhou, Xiaoyuan Chen, Hong Zhang, Lin Xia, Xin Tong, Limin Zou, Ruimin Hao, Jianhong Pan, Xiao Zhao, Dongmei Chen, Yuanyuan Song, Yueli Qi, Ling Tang, Zhifang Liu, Rong Gao, Yuankai Shi, Zhimin Yang

“…Abstract Background On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy. …”
Get full text

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study by Carmine D'Aniello, Maria Giuseppa Vitale, Azzurra Farnese, Lorenzo Calvetti, Maria Maddalena Laterza, Carla Cavaliere, Chiara Della Pepa, Vincenza Conteduca, Anna Crispo, Ferdinando De Vita, Francesco Grillone, Enrico Ricevuto, Michele De Tursi, Rocco De Vivo, Marilena Di Napoli, Sabrina Chiara Cecere, Gelsomina Iovane, Alfonso Amore, Raffaele Piscitelli, Giuseppe Quarto, Salvatore Pisconti, Gennaro Ciliberto, Piera Maiolino, Paolo Muto, Sisto Perdona, Massimiliano Berretta, Luca Galli, Giacomo Cartenì, Ugo De Giorgi, Sandro Pignata, GAETANO FACCHINI, Sabrina Rossetti

“…Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. …”
Get full text

Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug by Bozhao li, Xiuping Zhang, Zhouliang Wu, Tianjiao Chu, Zhenlin Yang, Shuai Xu, Suying Wu, Yunkai Qie, Zefang Lu, Feilong Qi, Minggen Hu, Guodong Zhao, Jingyan Wei, Yuliang Zhao, Guangjun Nie, Huan Meng, Rong Liu, Suping Li

“…To address this need, a wound‐targeted nanodrug is developed, that contains an immune checkpoint inhibitor (anti‐PD‐L1)and an angiogenesis inhibitor (sorafenib)). These nanoparticles consist of highly biocompatible mesoporous silica (MSNP) that is surface‐coated with platelet membrane (PM) to achieve surgical site targeting in a self‐amplified accumulation manner. …”
Get full text

Wnt10b-overexpressing umbilical cord mesenchymal stem cells promote critical size rat calvarial defect healing by enhanced osteogenesis and VEGF-mediated angiogenesis by Yong Liu, Jiarui Fang, Quan Zhang, Xiaoguang Zhang, Yulin Cao, Wei Chen, Zengwu Shao, Shuhua Yang, Dongcheng Wu, Man Hung, Yingze Zhang, Wei Tong, Hongtao Tian

“…Conditioned media from HUCMSCsWnt10b also induced endothelial cells to form vessel tubes in a tube formation assay, which could be abolished by SU5416, an angiogenesis inhibitor. Conclusion: To our knowledge, this is the first study providing empirical evidence that HUCMSCsWnt10b can enhance their ability to heal calvarial bone defects via VEGF-mediated angiogenesis. …”
Get full text

Myo/Nog Cells Increase in Response to Elevated Intraocular Pressure and Mitigate Ganglion Cell Death in a Mouse Model of Glaucoma by Paul Lecker, Karanveer Johal, Alexa McGrath, John Spikes, Jake Bernstein, Victoria MacPherson, Rushil Brahmbhatt, Nada Fadl, Edgar Weyback-Liogier, Sarah Adams, Rachel Souza, E-Jine Tsai, Mark Martin, Jacquelyn Gerhart, Grezgorz Gorski, Federica De Cecco, Brian Heist, Sebastian Egberts, Mindy George-Weinstein, Arturo Bravo-Nuevo

“…M/N cells express the skeletal-muscle-specific transcription factor MyoD, the bone morphogenetic protein inhibitor Noggin, and brain-specific angiogenesis inhibitor 1 (BAI1). Glaucoma was induced by injecting microbeads into the anterior chamber (AC) of the right eye to obstruct the flow of aqueous humor into the trabecular meshwork. …”
Get full text

A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women by Jeannette T. Bensen, Mariaelisa Graff, Kristin L. Young, Praveen Sethupathy, Joel Parker, Chad V. Pecot, Kevin Currin, Stephen A. Haddad, Edward A. Ruiz-Narváez, Christopher A. Haiman, Chi-Chen Hong, Lara E. Sucheston-Campbell, Qianqian Zhu, Song Liu, Song Yao, Elisa V. Bandera, Lynn Rosenberg, Kathryn L. Lunetta, Christine B. Ambrosone, Julie R. Palmer, Melissa A. Troester, Andrew F. Olshan

“…These SNPs reside in a genomic location that includes both the predicted primary transcript of the noncoding miRNA gene MIR3065 and the first intron of the gene for brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2). Furthermore, miRNA-associated SNPs on chromosomes 1p32.3, 5q32, and 3p25.1 were the strongest signals for hormone receptor, luminal versus basal-like, and HER2 enrichment status, respectively. …”
Get full text

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent by Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu

“…KEY WORDS: Cancer, VEGFR2 kinase, Kinase inhibitor, Angiogenesis, Inhibitor selectivity…”
Get full text

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors by Suying Lu, Suying Lu, Ye Hong, Ye Hong, Huimou Chen, Huimou Chen, Liuhong Wu, Liuhong Wu, Feifei Sun, Feifei Sun, Juan Wang, Juan Wang, Jia Zhu, Jia Zhu, Yi Que, Yi Que, Lian Zhang, Lian Zhang, Zijun Zhen, Zijun Zhen, Xiaofei Sun, Xiaofei Sun, Junting Huang, Junting Huang, Yizhuo Zhang, Yizhuo Zhang

“…This study aimed to evaluate the efficacy and safety of anlotinib, a novel oral multi-kinase angiogenesis inhibitor, in pediatric patients with refractory or recurrent solid tumors.Methods: This single-institutional, observational retrospective study was conducted in Sun Yat-sen University Cancer Center, China. …”
Get full text

SAIF plays anti-angiogenesis via blocking VEGF-VEGFR2-ERK signal in tumor treatment by Junye Xie, Fu Li, Yuling Cai, Jinting Zhang, Yibo Zhang, Zhaodong Zhai, Zijian Su, Xue Chen, Minghua Lei, Rongzhan Liu, Weicai Li, Dianlong Kang, Xiaojia Chen, An Hong

“…The evidence showed that SAIF, which is expressed by, is a potent and safe angiogenesis inhibitor and might be developed as a candidate peptide drug for the treatment of solid tumors such as hepatocellular carcinoma and other conditions linked with angiogenic overgrowth.…”
Get full text

The Vasohibin Family by Yasufumi Sato

“…A number of endogenous angiogenesis inhibitors have been found in the body. The origin of these inhibitors is mostly extrinsic to the vasculature. …”
Get full text

Targeting angiogenesis in melanoma: prospects for the future by P.G. Corrie, B. Basu, K. Ahmad Zaki

“…A variety of angiogenesis inhibitors are currently being tested in both metastatic and adjuvant melanoma clinical trials. …”
Get full text